Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
about
Positron Emission Tomography Imaging of Tumor Cell Metabolism and Application to Therapy Response MonitoringAnatomical, Physiological, and Molecular Imaging for Pancreatic Cancer: Current Clinical Use and Future ImplicationsChallenges of Pancreatic Cancer.Initial evaluation of 18F-fluorothymidine (FLT) PET/CT scanning for primary pancreatic cancer.Autoimmune pancreatitis in the context of IgG4-related disease: review of imaging findingsAdvances in diagnosis, treatment and palliation of pancreatic carcinoma: 1990-2010.Applying PET to broaden the diagnostic utility of the clinically validated CA19.9 serum biomarker for oncology.Metabolic positron emission tomography imaging in cancer detection and therapy response.Human pancreatic cancer tumors are nutrient poor and tumor cells actively scavenge extracellular protein.Site-specifically labeled CA19.9-targeted immunoconjugates for the PET, NIRF, and multimodal PET/NIRF imaging of pancreatic cancer.Positron emission tomography: clinical applications in oncology. Part 2.Autoimmune pancreatitis: proposal of IgG4-related sclerosing diseaseAcute recurrent pancreatitis: an autoimmune disease?Imaging heterogeneity in the mitochondrial redox state of premalignant pancreas in the pancreas-specific PTEN-null transgenic mouse modelPrognostic value of 18F-fluorodeoxyglucose positron emission tomography in patients with resectable pancreatic cancer.Diagnostic usefulness of an amino acid tracer, α-[N-methyl-(11)C]-methylaminoisobutyric acid ( (11)C-MeAIB), in the PET diagnosis of chest malignancies.Role of endoscopic ultrasound in pancreatic cancer.The current role of PET-CT in the characterization of hepatobiliary malignancies.Role of PET/CT imaging in stereotactic body radiotherapy.Amendment of the Japanese Consensus Guidelines for Autoimmune Pancreatitis, 2013 I. Concept and diagnosis of autoimmune pancreatitis.The role of ¹⁸F-FDG PET imaging in upper gastrointestinal malignancies.Metabolic signatures of malignant and non-malignant mass-forming lesions in the periampulla and pancreas in FDG PET/CT scan: an atlas with pathologic correlation.Imaging modalities for characterising focal pancreatic lesions.Energy sources identify metabolic phenotypes in pancreatic cancer.3'-Deoxy-3'-¹⁸F-fluorothymidine positron emission tomography as an early predictor of disease progression in patients with advanced and metastatic pancreatic cancer.Is (18)F-fluorodeoxyglucose positron emission tomography meaningful for estimating the efficacy of corticosteroid therapy in patients with autoimmune pancreatitis?Imaging findings of recurrent pancreatic cancer following resection.Fluorodeoxyglucose-positron emission tomography/computed tomography performs better than contrast-enhanced computed tomography for metastasis evaluation in the initial staging of pancreatic adenocarcinoma.The usefulness of (18)F-FDG PET/MRI fusion image in diagnosing pancreatic tumor: comparison with (18)F-FDG PET/CT.RAGE-specific single chain Fv for PET imaging of pancreatic cancer.18F-FDG PET with or without CT in the diagnosis of extrahepatic metastases or local residual/recurrent hepatocellular carcinoma
P2860
Q26765882-F9B5A12D-FD35-4B1D-B580-697BA675FE2BQ26996400-D10256C0-A6C3-4F10-B849-EDDBD4D4D2A6Q28080671-4D7279E3-09BA-44B8-8AF1-2EAFCE1C0E6BQ34090293-7F6555D8-D489-4295-BEF1-5A86484419DBQ34467195-83FBBED4-3A5B-4F2A-B4E7-4896919954B3Q34635042-D988E726-EFD7-49DB-AA88-C628FF49CFAFQ34762185-4CBA430D-6B8D-4E34-BD96-0B5615ABA36AQ34786518-DEC51CD0-A636-403E-ADDB-D311649FEE5CQ35046706-6850963B-F209-493E-9985-0EE9C3EE1CB5Q36435260-0A33E3F1-2B4F-4B50-B641-915A265227BEQ36448703-C86F457A-6DED-4F5B-A15E-38DD3F70BF6FQ36577659-798078B2-ACA9-4C8D-B303-D0ABFF90EC4EQ37089190-5E50BA34-A73E-46B1-8FA4-8DD6AB3C9DB2Q37180312-419CD72C-F077-45D4-946E-89DDEF1A4EA1Q37259570-F86ECFEA-C580-41A4-8643-F290B1410E1FQ37314320-E0496998-FB3B-42B3-B60C-C9CDE08FD5FFQ37503384-422615C4-E334-49D8-85E8-0917AC65CF6DQ37546832-8D8E44DC-7E80-4A06-981A-D3CA2FF63E8EQ37690317-B1ED0A26-F6E9-438D-AA52-739D3E85E91AQ38196746-E62E0948-85BD-4E4F-BDDF-DBB6E99A6E52Q38234184-9DB3121F-C2FF-4EDA-9BDD-DFEDA849A0D7Q38258220-3336B34D-22A9-48C0-A911-F2E4A75F3BEEQ38834240-BC9AE957-0BE2-4361-9686-DF51DC5AEDB1Q38959840-8CA025D0-82D7-4A3B-9681-720A4FAB07B4Q41448654-33AFBB2E-29EE-4D0A-981A-D8FDDA2E9017Q43281646-32BCF734-3075-4563-B9A6-B613AFD02BDFQ48047425-492B149C-5631-4F95-B01A-F7A31191CC3EQ48156217-763F6924-3205-4B11-82B3-F35B5BCE675EQ53113401-C14F32AF-DA03-4002-84B2-322F094B279DQ55191109-3ABEDEDE-7668-497D-90A2-7D2A7AB9F66AQ58706794-D31E4F38-5B28-4F7F-87B1-150F4FE66626
P2860
Diagnosis of pancreatic cancer using fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) --usefulness and limitations in "clinical reality".
description
2003 nî lūn-bûn
@nan
2003 թուականի Յունիսին հրատարակուած գիտական յօդուած
@hyw
2003 թվականի հունիսին հրատարակված գիտական հոդված
@hy
2003年の論文
@ja
2003年学术文章
@wuu
2003年学术文章
@zh-cn
2003年学术文章
@zh-hans
2003年学术文章
@zh-my
2003年学术文章
@zh-sg
2003年學術文章
@yue
name
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@ast
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@en
type
label
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@ast
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@en
prefLabel
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@ast
Diagnosis of pancreatic cancer ...... tations in "clinical reality".
@en
P2093
P2860
P356
P1476
Diagnosis of pancreatic cancer ...... itations in "clinical reality"
@en
P2093
Junji Konishi
Koji Fujimoto
Masayuki Imamura
Takayoshi Ishimori
Tatsuya Higashi
Tsuneo Saga
Yuji Nakamoto
P2860
P2888
P304
P356
10.1007/BF02988521
P577
2003-06-01T00:00:00Z